Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008](S0168827817321347)(10.1016/j.jhep.2017.06.026))
Journal
Journal of Hepatology
Journal Volume
69
Journal Issue
4
Pages
990-991
Date Issued
2018
Author(s)
SDGs
Publisher
Elsevier B.V.
Type
corrigendum